Trastuzumab emtansine: a game changer in HER2-positive early breast cancer

被引：2
作者：
Mano, Max S. [1 ]
机构：
[1] Hosp Sirio Libanes, Oncol Ctr, Rua Dona Adma Jafet 91, BR-01308050 Sao Paulo, SP, Brazil
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 32期
关键词：
early breast cancer; pathological complete response; T-DM1; trastuzumab; trastuzumab emtansine; GROWTH-FACTOR RECEPTOR; RESIDUAL INVASIVE DISEASE; PATHOLOGICAL COMPLETE RESPONSE; PERTUZUMAB PLUS TRASTUZUMAB; FREE CHEMOTHERAPY REGIMENS; DE-ESCALATION STRATEGIES; PREDIX HER2 TRIAL; ADJUVANT TRASTUZUMAB; OPEN-LABEL; NEOADJUVANT THERAPY;
D O I：
10.2217/fon-2020-0219
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1`s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC.
引用
收藏
页码：2595 / 2609
页数：15
相关论文
共 76 条
[1]   First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer [J].
Amiri-Kordestani, Laleh ;
Wedam, Suparna ;
Zhang, Lijun ;
Tang, Shenghui ;
Tilley, Amy ;
Ibrahim, Amna ;
Justice, Robert ;
Pazdur, Richard ;
Cortazar, Patricia .
CLINICAL CANCER RESEARCH, 2014, 20 (21) :5359-5364
[2]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[3]   Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard? [J].
Bergh, Jonas C. S. ;
Andersson, Anne ;
Bjohle, Judith ;
Bosch, Ana ;
Carlsson, Lena ;
Dreifaldt, Ann Charlotte ;
Einbeigi, Zakaria ;
Fredholm, Hanna ;
Isaksson-Friman, Erika ;
Foukakis, Theodoros ;
Elinder, Ellinor ;
Hellstrom, Mats ;
Johansson, Hemming ;
Lekberg, Tobias ;
Lindman, Henrik ;
Maes, Claudia ;
Brandberg, Yvonne ;
Hatschek, Thomas .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[4]   Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval [J].
Berry, Donald A. ;
Hudis, Clifford A. .
JAMA ONCOLOGY, 2015, 1 (07) :875-876
[5]   Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer. [J].
Brandberg, Yvonne ;
Andersson, Anne ;
Bjohle, Judith ;
Bosch, Ana ;
Carlsson, Lena ;
Dreifaldt, Ann Charlotte ;
Einbeigi, Zakaria ;
Fredholm, Hanna ;
Isaksson-Friman, Erika ;
Foukakis, Theodoros ;
Elinder, Ellinor ;
Hellstrom, Mats ;
Johansson, Hemming ;
Lekberg, Tobias ;
Lindman, Henrik ;
Bergh, Jonas C. S. ;
Hatschek, Thomas .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6]   11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].
Cameron, David ;
Piccart-Gebhart, Martine J. ;
Gelber, Richard D. ;
Procter, Marion ;
Goldhirsch, Aron ;
de Azambuja, Evandro ;
Castro, Gilberto, Jr. ;
Untch, Michael ;
Smith, Ian ;
Gianni, Luca ;
Baselga, Jose ;
Al-Sakaff, Nedal ;
Lauer, Sabine ;
McFadden, Eleanor ;
Leyland-Jones, Brian ;
Bell, Richard ;
Dowsett, Mitch ;
Jackisch, Christian .
LANCET, 2017, 389 (10075) :1195-1205
[7]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[8]   Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J].
de Azambuja, Evandro ;
Holmes, Andrew P. ;
Piccart-Gebhart, Martine ;
Holmes, Eileen ;
Di Cosimo, Serena ;
Swaby, Ramona F. ;
Untch, Michael ;
Jackisch, Christian ;
Lang, Istvan ;
Smith, Ian ;
Boyle, Frances ;
Xu, Binghe ;
Barrios, Carlos H. ;
Perez, Edith A. ;
Azim, Hatem A., Jr. ;
Kim, Sung-Bae ;
Kuemmel, Sherko ;
Huang, Chiun-Sheng ;
Vuylsteke, Peter ;
Hsieh, Ruey-Kuen ;
Gorbunova, Vera ;
Eniu, Alexandru ;
Dreosti, Lydia ;
Tavartkiladze, Natalia ;
Gelber, Richard D. ;
Eidtmann, Holger ;
Baselga, Jose .
LANCET ONCOLOGY, 2014, 15 (10) :1137-1146
[9]   AXILLARY LYMPH NODE SONOGRAPHIC FEATURES AND BREAST TUMOR CHARACTERISTICS AS PREDICTORS OF MALIGNANCY: A NOMOGRAM TO PREDICT RISK [J].
de Camargo Teixeira, Patricia Akissue ;
Chala, Luciano F. ;
Shimizu, Carlos ;
Filassi, Jose R. ;
Maesaka, Jonathan Y. ;
de Barros, Nestor .
ULTRASOUND IN MEDICINE AND BIOLOGY, 2017, 43 (09) :1837-1845
[10]  
Denkert C, 2020, J CLIN ONCOL, V38
12345678